55% Self-Pay Mix for Zepbound Raises Risk as Lilly Trades at 14x Sales
LLY•Eli Lilly's obesity drug Zepbound accounted for 55% of new prescriptions via out-of-pocket payments in the most recent quarter, up from 50% previously, exposing the company to price-sensitive consumer risk. Shares, up 45% over the year, trading at a price-to-sales multiple of 14, may be vulnerable if self-pay demand wanes.
1. Self-Pay Prescriptions Dominate Zepbound Growth
In the most recent quarter, new Zepbound prescriptions filled via out-of-pocket payments reached 55%, up from 50% in the prior quarter. This indicates strong demand from self-pay patients but highlights a reliance on consumers who make monthly purchasing decisions without insurance coverage.
2. Valuation Concerns and Revenue Durability
Eli Lilly's shares are up 45% over the past year and trade at a 14x price-to-sales multiple, reflecting premium growth expectations. The high self-pay mix exposes a significant portion of revenue to price sensitivity and competitive pressure, challenging the durability of its growth thesis.
